PBIRx®
Intelligent Solutions in Pharmacy Benefits
612 Wheelers Farms Road, Milford, CT 06461
(888) 797-2479
The latest in cancer treatment news explains that a new drug
designed specifically for blood cancer may be on its way to receiving FDA
approval. The drug, known as elotuzumab, comes from Bristol-Myers Squibb and
AbbVie. The two have planned to market this multiple myeloma treatment as
“Empliciti,” and have labeled it for those patients who have already been
through one or more rounds of therapy treatment, explains FierceBiotech. As it
has been given priority review by the FDA, we should know if the drug is approved
within the next 6 months.
The history of
elotuzumab
Though this is recent news, the drug has been up in the air
since 2008. At this time, Bristol-Myers licensed it from PDL BioPharma for the
high price of $30 million. When AbbVie emerged in 2013, they and Bristol-Myers
paired together and continued to work on the drug that could potentially bring
relief for those who suffer from multiple myeloma.
The research
FierceBiotech reports that in Phase III results, the
combination of elotuzumab, Celgene’s Revlimid and the generic dexamethasone
proved its worth by beating two older drugs. However, before that, due to its
success in Phase II, the FDA granted it “breakthrough-therapy designation”
earlier on. This allows the creators of the drug to access high level officials
throughout the entire process of being developed.
To learn more about elotuzumab and its path to FDA approval,
please click here.
At PBIRx,
we work hard to stay on top of all of the latest pharmaceutical news to ensure
that we are prepared for any new approvals before they come. If you have
questions about this blood cancer drug and how it may impact your pharmacy
benefit plan if it should be approved, please contact us to learn more about
how our services can help; we can be reached at (888) 797-2479 or through our contact form on our website.
No comments:
Post a Comment